News | Prostate Cancer | January 05, 2024

Mayo Clinic’s PSMA Alpha-PET DoubLET platform allows for imaging and targeted therapy with alpha and/or beta-particle radiopharmaceutical therapy (RPT) using a novel 64/67Cu and 203/212Pb double chelator design

Mayo Clinic’s PSMA Alpha-PET DoubLET platform allows for imaging and targeted therapy with alpha and/or beta-particle radiopharmaceutical therapy (RPT) using a novel 64/67Cu and 203/212Pb double chelator design

Getty Images


January 5, 2024 — Perspective Therapeutics, Inc., announced that it has entered into a patent license agreement with Mayo Clinic for the rights to the PSMA Alpha-PET DoubLET platform technology for the treatment of PSMA-expressing cancers, with an initial focus on prostate.

The PSMA Alpha-PET DoubLET platform technology represents a potential leap forward in the field of prostate cancer diagnostics and treatment. This leading radiopharmaceutical platform provides detailed PET imaging-based diagnosis and dosimetry using long-lived copper-64 (64Cu) for imaging and alpha-particle targeted RPT using lead-212 (212Pb). It can also be used for beta-particle targeted RPT using copper isotopes. Preclinical studies demonstrated a high degree of radiation delivered to tumors while minimizing exposure to critical organs and tissues.

“This innovative approach developed by Mayo Clinic allows for more precise and personalized treatment plans,” said Thijs Spoor, Chief Executive Officer at Perspective Therapeutics. “This new license furthers our goal to bring new best-in-class products to the clinic that improve efficacy and minimize side effects.”

“It is not enough to develop a more powerful therapy. We focused on diagnostic accuracy, patient tolerance and convenience. PSMA Alpha-PET aims to improve the overall experience of individuals undergoing prostate cancer radiopharmaceutical therapy,” commented co-inventor Geoff Johnson, MD, PhD, Chair of Nuclear Medicine, Associate Director of the Mayo Clinic Comprehensive Cancer Center and Director of the Radiopharmaceutical Trial Disease Team. “The platform’s innovative design provides rapid and high-quality quantitative PET imaging to guide alpha and/or beta-particle RPT, with a reasonable workflow that patients and clinics can follow.”

Co-inventor Mukesh Pandey, PhD, FRSC, Professor of Radiology and Director of Mayo Clinic Molecular Imaging Research Program said, “The team at Mayo Clinic conducted rigorous scientific experiments to validate the specific targeting of PSMA Alpha-PET to prostate tumors compared to other normal tissues. We are pleased to report that this compound performed very favorably in the preclinical setting where it had significantly less salivary gland uptake and improved kidney clearance than comparators. PSMA Alpha-PET was also effective in treating mice with prostate cancer tumor implants and was well tolerated.”

Dr. Markus Puhlmann, Chief Medical Officer of Perspective Therapeutics added, “PSMA Alpha-PET is a potentially groundbreaking solution that addresses some of the limitations of existing products in prostate cancer imaging and treatment. We are committed to advancing medical technology that we believe will make a meaningful difference in the lives of those affected by prostate cancer.”

For more information: www.perspectivetherapeutics.com


Related Content

News | Breast Imaging

February 22, 2024 — The FAST-Forward randomized trial from the UK found that ultrahypofractionated whole breast ...

Time February 22, 2024
arrow
News | Radiation Oncology

February 22, 2024 — The National Institutes of Health has launched a clinical trials network to evaluate emerging ...

Time February 22, 2024
arrow
News | Radiopharmaceuticals and Tracers

February 21, 2024 — Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next ...

Time February 21, 2024
arrow
News | Radiation Oncology

February 14, 2024 — Accuray Incorporated announced that the team at Quebec’s Montérégie Integrated Cancer Center, part ...

Time February 14, 2024
arrow
News | Radiation Oncology

February 12, 2024 — Radformation, a global pioneer in radiation oncology software solutions, is pleased to announce its ...

Time February 12, 2024
arrow
News | Quality Assurance (QA)

February 12, 2024 — IBA, a world leader in particle accelerator technology and a world-leading provider of dosimetry and ...

Time February 12, 2024
arrow
News | Radiation Therapy

February 8, 2024 — RaySearch Laboratories AB announced that The Royal Marsden NHS Foundation Trust, a specialist cancer ...

Time February 08, 2024
arrow
Videos | RSNA

At RSNA23, Imaging Technology News (ITN) spoke with Bhvita Jani, principal analyst at Signify Research, about ...

Time February 07, 2024
arrow
News | Interventional Radiology

February 6, 2024 — RenovoRx, Inc., a clinical-stage biopharmaceutical company developing novel precision oncology ...

Time February 06, 2024
arrow
News | Treatment Planning

February 2, 2024 — RaySearch Laboratories announced that the number of radiotherapy centers that have chosen RayStation ...

Time February 02, 2024
arrow
Subscribe Now